Stay informed with the latest mpox (formerly monkeypox) updates from the AMA.
Featured updates
Featured updates
- Dec. 7, 2023: Mpox Caused by Human-to-Human Transmission of Monkeypox Virus with Geographic Spread in the Democratic Republic of the Congo
- Oct. 6, 2022: CDC COCA Call: Situational Update for Clinicians about Severe Monkeypox Virus Infections
- Sept. 29, 2022: CDC HAN Health Advisory: Severe Manifestations of Monkeypox among People who are Immunocompromised Due to HIV or Other Conditions
- Aug. 11, 2022: CDC COCA Call: Interim Clinical Considerations for Monkeypox Vaccination
- Aug. 8, 2022: FDA news release: FDA authorizes emergency use of JYNNEOS vaccine
- July 27, 2022: Letter from CDC Director Rochelle Walensky, MD: Pain emerging as major issue with monkeypox infection; basic tools for managing the infection (PDF)
Clinical information and resources
Clinical information and resources
Find FAQs for physicians—including MPV testing and therapeutics—CDC guidance, CPT coding and more. Track the trends of cases reported to CDC.
Video updates with AMA and CDC experts
Video updates with AMA and CDC experts
What physicians need to know about tecovirimat (“TPOXX”) for mpox treatment
Experts from the AMA, FDA and CDC discuss tecovirimat, or TPOXX, for the treatment of mpox in infected individuals.
The facts about monkeypox with CDC experts
In this July 14, 2022, Moving Medicine video update, two experts from the CDC’s Division of High-Consequence Pathogens & Pathology, Caroline Schrodt, MD, and Jennifer McQuiston, DVM, share facts on MPV.
